trial

Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)

NCTId NCT00844922
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 16 (actual)
Sponsored by Merck Sharp & Dohme LLC
Primary completion 2006-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
16 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2005-09
Primary completion
2006-06
Eligibility
ALL · 18 Years · 75 Years

Interventions & indications

Drugs
SCH 900636

Sponsors

Merck Sharp & Dohme LLCLead Sponsor

Sites

0 total

Linked catalysts

1
Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Tria — primary completion2006-06

Facts & assertions

4 sourced
Enrollment
16
Phase
PHASE2
Primary Completion Date
2006-06
Status
COMPLETED
relationships
The graph out of here
drug
SCH 900636
drug
lead_sponsor
Merck Sharp & Dohme LLC
company
indication
Psychotic Disorders
indication
Depression
indication
Psychotic Disorders
indication